NASDAQ:FLGT

Fulgent Genetics Stock Forecast, Price & News

$86.19
-0.57 (-0.66 %)
(As of 09/16/2021 02:48 PM ET)
Add
Compare
Today's Range
$84.50
$87.33
50-Day Range
$74.87
$110.87
52-Week Range
$29.95
$189.89
Volume13,148 shs
Average Volume1.27 million shs
Market Capitalization$2.54 billion
P/E Ratio5.00
Dividend YieldN/A
Beta1.48
30 days | 90 days | 365 days | Advanced Chart
Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.


Fulgent Genetics logo

About Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Headlines

Fulgent Genetics (NASDAQ:FLGT) Trading Down 6.9%
Fulgent Genetics (NASDAQ:FLGT) Trading Down 6.9%
September 13, 2021 |  americanbankingnews.com
Fulgent Genetics (NASDAQ:FLGT) Trading 7.3% Higher
Fulgent Genetics (NASDAQ:FLGT) Trading 7.3% Higher
September 10, 2021 |  americanbankingnews.com
10 Million Reasons Im Not Selling Fulgent Genetics
10 Million Reasons I'm Not Selling Fulgent Genetics
September 2, 2021 |  finance.yahoo.com
Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells $56,757.50 in Stock
Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells $56,757.50 in Stock
September 1, 2021 |  americanbankingnews.com
Fulgent Genetics (NASDAQ:FLGT) Trading Down 3.3%
Fulgent Genetics (NASDAQ:FLGT) Trading Down 3.3%
August 24, 2021 |  americanbankingnews.com
Why Shares of Fulgent Genetics Are Plunging Today
Why Shares of Fulgent Genetics Are Plunging Today
August 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

758th out of 1,352 stocks

Medical Laboratories Industry

16th out of 30 stocks

Analyst Opinion: 1.1Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

Is Fulgent Genetics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics
or view top-rated stocks.

What stocks does MarketBeat like better than Fulgent Genetics?

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 3,850,000 shares, a drop of 14.3% from the July 29th total of 4,490,000 shares. Based on an average daily volume of 754,000 shares, the short-interest ratio is currently 5.1 days. Currently, 20.2% of the shares of the stock are short sold.
View Fulgent Genetics' Short Interest
.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Fulgent Genetics
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Monday, August, 9th. The company reported $2.47 EPS for the quarter, missing the Zacks' consensus estimate of $2.54 by $0.07. The firm earned $153.60 million during the quarter, compared to analyst estimates of $197.34 million. Fulgent Genetics had a trailing twelve-month return on equity of 78.71% and a net margin of 54.24%. The business's revenue was up 789.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 earnings per share.
View Fulgent Genetics' earnings history
.

How has Fulgent Genetics' stock price been impacted by Coronavirus?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLGT stock has increased by 756.8% and is now trading at $86.19.
View which stocks have been most impacted by COVID-19
.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics issued an update on its third quarter 2021 earnings guidance on Monday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $125 million-$150 million, compared to the consensus revenue estimate of $146.10 million.

What price target have analysts set for FLGT?

5 equities research analysts have issued 1-year price objectives for Fulgent Genetics' shares. Their forecasts range from $42.00 to $140.00. On average, they anticipate Fulgent Genetics' share price to reach $94.25 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts' price targets for Fulgent Genetics
or view top-rated stocks among Wall Street analysts.

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Ming Hsieh, Chairman, President & Chief Executive Officer
  • James Xie, Chief Operating Officer
  • Paul H. Kim, Chief Financial Officer
  • Harry Gao, Chief Scientific Officer & Laboratory Director
  • Lawrence M. Weiss, Chief Medical Officer

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.54%), Vanguard Group Inc. (4.41%), State Street Corp (2.10%), Susquehanna International Group LLP (0.00%), Morgan Stanley (1.25%) and Morgan Stanley (1.23%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics
.

Which major investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Morgan Stanley, Citadel Advisors LLC, Russell Investments Group Ltd., Millennium Management LLC, Marshall Wace LLP, and Marshall Wace LLP. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics
or view top insider-selling stocks.

Which major investors are buying Fulgent Genetics stock?

FLGT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., JPMorgan Chase & Co., State Street Corp, Capital Fund Management S.A., Geode Capital Management LLC, First Trust Advisors LP, and Skandinaviska Enskilda Banken AB publ.
View insider buying and selling activity for Fulgent Genetics
or or view top insider-buying stocks.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $86.19.

How much money does Fulgent Genetics make?

Fulgent Genetics has a market capitalization of $2.54 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $8.85 on an earnings per share basis.

How many employees does Fulgent Genetics have?

Fulgent Genetics employs 429 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Where are Fulgent Genetics' headquarters?

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at (626) 350-0537 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.